S. Nattam

发表

A phase IB/randomized phase II study of gemcitabine (G) plus placebo (P) or vismodegib (V), a hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic pancreatic cancer (PC): Interim analysis of a University of Chicago phase II consortium study.

M. Vannier, M. Edelman, H. Lenz, 2012 .

Final analysis of a phase IB/randomized phase II study of gemcitabine (G) plus placebo (P) or vismodegib (V), a hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic pancreatic cancer (PC): A University of Chicago phase II consortium study.

M. Vannier, H. Lenz, W. Stadler, 2013 .

A phase II study of lapatinib (GW572016) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).

J. Dancey, E. Vokes, E. Cohen, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901

J. Byrd, R. Larson, K. Rai, 2009, Leukemia & lymphoma.

Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01–24/USO-023

C. Yiannoutsos, N. Hanna, R. Govindan, 2007 .

Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002

J. Byrd, B. Cheson, R. Larson, 2014, British journal of haematology.

Pemetrexed plus Cetuximab in Patients with Recurrent Non-small Cell Lung Cancer (NSCLC): A Phase I/II Study from the Hoosier Oncology Group

N. Hanna, M. Edelman, Menggang Yu, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer.

E. Kohn, W. Barry, M. Birrer, 2019 .

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL

Scott E. Smith, Allison M. Booth, J. Byrd, 2018, The New England journal of medicine.

A Phase II Study of Erlotinib and Bevacizumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

E. Vokes, D. Yan, K. Stenson, 2009 .

High‐Dose Cimetidine for the Treatment of Metastatic Renal Cell Carcinoma: A Hoosier Oncology Group Study

S. Nattam, Stephen D. Williams, D. Stephens, 1992, American journal of clinical oncology.

Bevacizumab (B) plus gemcitabine (G) in patient (pts) with advanced pancreatic cancer (PC): Updated results of a multi-center phase II trial.

E. Vokes, W. Stadler, H. Kindler, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bevacizumab (B) plus gemcitabine (G) in patient (pts) with advanced pancreatic cancer (PC): Updated results of a multi-center phase II trial.

E. Vokes, W. Stadler, H. Kindler, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sorafenib (S) plus gemcitabine (G) for advanced pancreatic cancer (PC): A phase II trial of the University of Chicago Phase II Consortium

E. Vokes, W. Stadler, H. Kindler, 2007 .

Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan

C. Bloomfield, R. Larson, Daohai Yu, 2009, Cancer.

Mature results from Hoosier Oncology Group GU04-75 phase II trial of cisplatin (C), gemcitabine (G), and bevacizumab (B) as first-line chemotherapy for metastatic urothelial carcinoma (UC).

Cynthia S. Johnson, S. Perkins, R. Zon, 2010 .

Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer

R. Salgia, H. Lenz, F. D. de Sauvage, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.

E. Kohn, E. Winer, W. Barry, 2014, The Lancet. Oncology.

Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas

Sonali M. Smith, Krishna Rao, A. Rapoport, 2020, Haematologica.

Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A041202

Scott E. Smith, Allison M. Booth, J. Byrd, 2018, Blood.

A phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer.

E. Vokes, H. Kindler, C. Eng, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation.

M. Perry, C. Belani, G. Mills, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.

J. Dancey, E. Vokes, T. Seiwert, 2009, The Lancet. Oncology.

Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology.

Cynthia S. Johnson, Constantin Yiannoutsos, Thomas Anderson, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75.

Cynthia S. Johnson, S. Perkins, R. Zon, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202

Scott E. Smith, Allison M. Booth, J. Byrd, 2021, Leukemia.

A Phase II Study of Lapatinib in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Jeffrey Bozeman, J. Dancey, E. Vokes, 2012, Clinical Cancer Research.

Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium

E. Vokes, W. Stadler, M. Hall, 2012, Investigational New Drugs.

Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer.

A. Dachman, E. Vokes, W. Stadler, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A multi-center phase II study of arsenic trioxide (AT) in patients (Pts) with advanced pancreatic cancer (PC) refractory to gemcitabine

E. Vokes, H. Kindler, S. Nattam, 2004 .

A multi-center phase II study of arsenic trioxide (AT) in patients (Pts) with advanced pancreatic cancer (PC) refractory to gemcitabine.

E. Vokes, H. Kindler, S. Nattam, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer.

E. Kohn, W. Barry, M. Birrer, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized, Double-Blinded, Multicenter, Phase II Study of Pemetrexed, Carboplatin, and Bevacizumab with Enzastaurin or Placebo in Chemonaïve Patients with Stage IIIB/IV Non-small Cell Lung Cancer: Hoosier Oncology Group LUN06-116

N. Hanna, J. Latz, J. Patel, 2010, Journal of Thoracic Oncology.

A multicenter phase II study of cisplatin (C), gemcitabine (G), and bevacizumab (B) as first-line chemotherapy for metastatic urothelial carcinoma (UC): Hoosier Oncology Group GU-0475.

S. Perkins, R. Zon, J. Picus, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase III hoosier oncology group study of thoracic radiotherapy (TRT) plus cisplatin (P) and vinblastin (V) with or without hydroxgurea (HX) for locally unresectable non small cell lung cancer (NSCLC)

L. Einhorn, A. Sandler, J. Montebello, 1998 .

Arsenic Trioxide in Patients With Adenocarcinoma of the Pancreas Refractory to Gemcitabine: A Phase II Trial of the University of Chicago Phase II Consortium

E. Vokes, H. Kindler, S. Nattam, 2008, American journal of clinical oncology.

Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy

Scott E. Smith, Allison M. Booth, J. Byrd, 2021, Blood.

Treatment of Elderly Non–small Cell Lung Cancer Patients with Three Different Schedules of Weekly Paclitaxel in Combination with Carboplatin: Subanalysis of a Randomized Trial

S. Ramalingam, M. Perry, C. Belani, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II Study of the Oral MEK Inhibitor AZD6244 in Advanced Acute Myeloid Leukemia (AML).

Scott E. Smith, R. Larson, W. Stock, 2009 .

Phase II Study of Temsirolimus and Lenalidomide in Patients with Relapsed and Refractory Lymphomas: Final Analysis of NCI 8309

Sonali M. Smith, Krishna Rao, A. Rapoport, 2016 .

Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002

J. Byrd, B. Cheson, R. Larson, 2014, British journal of haematology.

Overall survival and updated progression-free survival results from a randomized phase 2 trial comparing the combination of olaparib and cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer.

E. Kohn, W. Barry, M. Birrer, 2017 .